List of Excipients in Branded Drug CYCLOBENZAPRINE HYDROCHLORIDE

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Teva Pharmaceuticals USA Inc	CYCLOBENZAPRINE HYDROCHLORIDE	cyclobenzaprine hydrochloride	0093-1920	D&C YELLOW NO. 10
Teva Pharmaceuticals USA Inc	CYCLOBENZAPRINE HYDROCHLORIDE	cyclobenzaprine hydrochloride	0093-1920	DIETHYL PHTHALATE
Teva Pharmaceuticals USA Inc	CYCLOBENZAPRINE HYDROCHLORIDE	cyclobenzaprine hydrochloride	0093-1920	ETHYLCELLULOSE

Generic Drugs Containing CYCLOBENZAPRINE HYDROCHLORIDE

Company	Ingredient	NDC	Excipient
Teva Pharmaceuticals USA Inc	cyclobenzaprine hydrochloride	0093-3420	CALCIUM PHOSPHATE, DIBASIC, ANHYDROUS
Teva Pharmaceuticals USA Inc	cyclobenzaprine hydrochloride	0093-3420	CELLULOSE, MICROCRYSTALLINE
Teva Pharmaceuticals USA Inc	cyclobenzaprine hydrochloride	0093-3420	CROSCARMELLOSE SODIUM

What are the Most Frequently-Used Excipients in CYCLOBENZAPRINE HYDROCHLORIDE?

# Of NDCs	Excipient
1	ACID YELLOW 3
13	ALCOHOL
2	ALUMINUM OXIDE

Excipient Strategy and Commercial Opportunities for Cyclobenzaprine Hydrochloride

Last updated: March 2, 2026

What are the key considerations in the excipient strategy for cyclobenzaprine hydrochloride (CBZ)?

Cyclobenzaprine hydrochloride (CBZ) is a skeletal muscle relaxant used primarily to treat muscle spasms. Its formulation typically involves excipients that enhance stability, bioavailability, masking taste, and ensure manufacturability. The excipient strategy centers on:

• Matrix Formation: Using binders like microcrystalline cellulose or povidone to create a stable tablet matrix.
• Disintegration and Dissolution: Incorporating disintegrants such as croscarmellose sodium to facilitate release.
• Stability Enhancers: Using antioxidants like ascorbic acid or EDTA to maintain chemical stability.
• Taste Masking: Applying flavoring agents or coating technologies to improve patient acceptance, particularly in oral formulations.

What are the common excipients used in CBZ formulations?

Excipients Type	Examples	Purpose
Binders	Microcrystalline cellulose, povidone	Maintain tablet integrity
Disintegrants	Croscarmellose sodium, sodium starch glycolate	Facilitate tablet breakup
Fillers	Lactose, dibasic calcium phosphate	Volume expansion and ease of compression
Disguising agents	Flavors, sweeteners	Mask bitter taste
Lubricants	Magnesium stearate	Ease tablet ejection
Coatings	Polymer-based films	Taste masking, controlled release

What are commercial opportunities in excipient development?

1. Innovative Taste Masking Technologies

Given CBZ's bitterness, investment in advanced taste masking coatings, such as lipid layers or polymer films that dissolve in the gastrointestinal tract, offers differentiation. Technologies like Meltrex or Opadry enable targeted release and better patient compliance.

2. Modified-Release Formulations

Formulating controlled-release tablets using excipients like hydroxypropyl methylcellulose (HPMC) or ethylcellulose can extend dosing intervals. These formulations reduce dosing frequency, improving adherence for chronic use.

3. High-Load, Low-Excipient Formulations

Developing low-excipient, high-loading formulations will minimize size and improve patient tolerability, especially in large-dose scenarios common with CBZ.

4. Specialized Excipients for Stability

Using antioxidants or chelating agents in formulations to enhance shelf life aligns with regulatory standards for longer expiry periods. Market players investing in such excipients gain a competitive edge.

5. Orally Disintegrating Tablets (ODT)

Developing ODT formulations with fast disintegrants like crospovidone offers convenience for patients with swallowing difficulties, expanding patient base.

Market Size and Growth

The global market for muscle relaxants, including CBZ, is expected to grow at a Compound Annual Growth Rate (CAGR) of approximately 3.7% from 2022 to 2028 [1]. The excipient segment within this market is projected to expand at a similar rate, driven by demand for innovative formulations.

Patent and Regulatory Landscape

• Patent filings related to excipient formulations of CBZ focus on taste masking, controlled release, and stability.
• Regulatory agencies like the FDA emphasize safety and efficacy in excipient selection, influencing R&D investments.

Strategic Partnerships

Collaborations between pharmaceutical companies and excipient suppliers are common in developing tailored excipient systems that meet specific bioavailability and stability criteria.

How do excipient choices influence market differentiation?

Efficient excipient design improves product stability, bioavailability, and user experience. For CBZ, this contrasts with generic competitors that may employ standard excipients, offering a chance for branded formulations with superior attributes.

What are regulatory influences on excipient strategies?

Regulatory authorities scrutinize excipient safety profiles, manufacturing processes, and documentation. Recent guidance emphasizes transparency and justification for excipient use, influencing formulation selection and development timelines.

---

Key Takeaways

• Excipient strategy for CBZ focuses on taste masking, stability, controlled release, and patient adherence.
• Opportunities include advanced taste masking technologies, modified-release systems, low-excipient formulations, and ODT options.
• Innovation in excipient systems can provide differentiation, improve market share, and meet regulatory expectations.
• The market for muscle relaxant formulations is growing, with excipient development critical for competitive advantage.
• Strategic partnerships with excipient suppliers support the development of proprietary, high-performance formulations.

---

FAQs

Q1: What challenges are associated with formulating CBZ?
Formulation challenges include masking its bitter taste, ensuring chemical stability over shelf life, and developing controlled-release systems without compromising bioavailability.

Q2: Are there specific regulatory concerns for excipients in CBZ formulations?
Yes, excipients must be Generally Recognized as Safe (GRAS) or approved, with thorough documentation on their safety, compatibility, and manufacturing processes.

Q3: What excipient innovations are most impactful for CBZ?
Taste masking coatings, disintegrants that enable fast dissolution, and controlled-release polymers significantly impact product performance.

Q4: How large is the market for CBZ excipient development?
While specific figures are not available, the broader muscle relaxant market is expanding at a CAGR of approximately 3.7%, with excipient demand following suit.

Q5: What are the future trends in excipient strategies for CBZ?
Emphasis on patient-centric formulations like ODTs, environmentally friendly excipients, and formulations enabling personalized dosing are emerging trends.

---

References

[1] MarketWatch. (2022). Muscle Relaxants Market Size, Trends, and Forecasts 2022–2028. Retrieved from https://www.marketwatch.com